NovoCure Statistics
Total Valuation
NovoCure has a market cap or net worth of $1.34 billion. The enterprise value is $1.11 billion.
| Market Cap | 1.34B |
| Enterprise Value | 1.11B |
Important Dates
The last earnings date was Thursday, October 29, 2026, before market open.
| Earnings Date | Oct 29, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
NovoCure has 116.92 million shares outstanding. The number of shares has increased by 3.87% in one year.
| Current Share Class | 116.92M |
| Shares Outstanding | 116.92M |
| Shares Change (YoY) | +3.87% |
| Shares Change (QoQ) | +0.67% |
| Owned by Insiders (%) | 8.66% |
| Owned by Institutions (%) | 82.77% |
| Float | 97.37M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.86 |
| Forward PS | 1.72 |
| PB Ratio | 3.76 |
| P/TBV Ratio | 3.85 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.54 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.49, with a Debt / Equity ratio of 0.66.
| Current Ratio | 2.49 |
| Quick Ratio | 2.30 |
| Debt / Equity | 0.66 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -4.30 |
Financial Efficiency
Return on equity (ROE) is -35.18% and return on invested capital (ROIC) is -95.37%.
| Return on Equity (ROE) | -35.18% |
| Return on Assets (ROA) | -6.79% |
| Return on Invested Capital (ROIC) | -95.37% |
| Return on Capital Employed (ROCE) | -21.33% |
| Weighted Average Cost of Capital (WACC) | 10.11% |
| Revenue Per Employee | $451,955 |
| Profits Per Employee | -$75,844 |
| Employee Count | 1,605 |
| Asset Turnover | 0.66 |
| Inventory Turnover | 4.14 |
Taxes
| Income Tax | -8.81M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -1.18% in the last 52 weeks. The beta is 1.09, so NovoCure's price volatility has been similar to the market average.
| Beta (5Y) | 1.09 |
| 52-Week Price Change | -1.18% |
| 50-Day Moving Average | 14.95 |
| 200-Day Moving Average | 14.79 |
| Relative Strength Index (RSI) | 32.37 |
| Average Volume (20 Days) | 1,978,758 |
Short Selling Information
The latest short interest is 12.82 million, so 10.97% of the outstanding shares have been sold short.
| Short Interest | 12.82M |
| Short Previous Month | 11.16M |
| Short % of Shares Out | 10.97% |
| Short % of Float | 13.17% |
| Short Ratio (days to cover) | 9.27 |
Income Statement
In the last 12 months, NovoCure had revenue of $725.39 million and -$121.73 million in losses. Loss per share was -$1.06.
| Revenue | 725.39M |
| Gross Profit | 560.38M |
| Operating Income | -119.04M |
| Pretax Income | -130.54M |
| Net Income | -121.73M |
| EBITDA | -103.49M |
| EBIT | -119.04M |
| Loss Per Share | -$1.06 |
Balance Sheet
The company has $463.48 million in cash and $231.55 million in debt, with a net cash position of $231.93 million or $1.98 per share.
| Cash & Cash Equivalents | 463.48M |
| Total Debt | 231.55M |
| Net Cash | 231.93M |
| Net Cash Per Share | $1.98 |
| Equity (Book Value) | 350.61M |
| Book Value Per Share | 3.12 |
| Working Capital | 402.86M |
Cash Flow
In the last 12 months, operating cash flow was -$722,000 and capital expenditures -$23.89 million, giving a free cash flow of -$24.61 million.
| Operating Cash Flow | -722,000 |
| Capital Expenditures | -23.89M |
| Depreciation & Amortization | 15.55M |
| Net Borrowing | -560.95M |
| Free Cash Flow | -24.61M |
| FCF Per Share | -$0.21 |
Margins
Gross margin is 77.25%, with operating and profit margins of -16.41% and -16.78%.
| Gross Margin | 77.25% |
| Operating Margin | -16.41% |
| Pretax Margin | -18.00% |
| Profit Margin | -16.78% |
| EBITDA Margin | -14.27% |
| EBIT Margin | -16.41% |
| FCF Margin | n/a |
Dividends & Yields
NovoCure does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -3.87% |
| Shareholder Yield | -3.87% |
| Earnings Yield | -9.25% |
| FCF Yield | -1.82% |
Analyst Forecast
The average price target for NovoCure is $26.14, which is 127.90% higher than the current price. The consensus rating is "Buy".
| Price Target | $26.14 |
| Price Target Difference | 127.90% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | 12.66% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
NovoCure has an Altman Z-Score of 0.69 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.69 |
| Piotroski F-Score | 5 |